ABCL

NASDAQ 已收盘

AbCellera Biologics

10.47 USD
▼-0.55-4.99%
盘后 10.30 -1.62%
2026-11-19
市值
$3.16B
市盈率
—
EPS
-0.48
股息率
—
52 周区间
2.75 – 15.02
成交量
2.50M
Beta
1.59
目标价
18.69
52W 低 2.7552W 高 15.02
价格走势

公司简介

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil...